Medicines and Healthcare products Regulatory Agency
The UK medicines and devices regulator, which since Brexit runs its own approvals, joins Project Orbis and uses international reliance routes to speed cancer drug access.
Formed in 2003 by merging the Medicines Control Agency and the Medical Devices Agency, the MHRA became the UK's standalone regulator for new medicines after the UK left the EU in 2021. It participates in the FDA-led Project Orbis and the Access Consortium (with Australia, Canada, Singapore and Switzerland), uses the International Recognition Procedure to rely on approvals by trusted regulators, and runs the Innovative Licensing and Access Pathway with NICE and the Scottish Medicines Consortium to align licensing and reimbursement. The MHRA also regulates clinical trials, devices including AI software, and blood and tissue products, and operates the Yellow Card safety scheme.
- Project Orbis and Access Consortium
- International Recognition Procedure
- Innovative Licensing and Access Pathway (with NICE and SMC)
- Clinical trials and device regulation
Pages like this
not linked directly; found by shared links- IdeaContinuous prospective validation for every oncology AI tool after deployment
Shares AI in radiology, Digital pathology & AI, AI that is built but not validated or deployed, Regulatory divergence between regions.
- InstitutionComisión Federal para la Protección contra Riesgos Sanitarios
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- IdeaA dedicated fund for randomised trials of cancer AI with patient outcomes
Shares AI in radiology, Digital pathology & AI, AI that is built but not validated or deployed.
- InstitutionPharmaceuticals and Medical Devices Agency
Shares European Medicines Agency, FDA Oncology Center of Excellence, Regulatory divergence between regions.
- IdeaFederated training of pathology and radiology models across hospitals
Shares AI in radiology, Digital pathology & AI, AI that is built but not validated or deployed.
- InstitutionPharmaceutical Benefits Advisory Committee
Shares Therapeutic Goods Administration, National Institute for Health and Care Excellence.
- IdeaA federated learning consortium of cancer centres that jointly own the models
Shares AI in radiology, Digital pathology & AI, AI that is built but not validated or deployed.
- InstitutionISPOR – The Professional Society for Health Economics and Outcomes Research
Shares Scottish Medicines Consortium, National Institute for Health and Care Excellence.